Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606057 | 0.88 | TRPV1 (0.52) | KMT2AMEN1LMNARAB9APTAFR | |
| SCHEMBL2935509 | 0.85 | SMN1; SMN2 (0.46) | KMT2AMEN1RAB9A | |
| SCHEMBL2930927 | 0.85 | HDAC1 (0.47) | RAB9APARP15 | |
| SCHEMBL2926141 | 0.84 | RAB9A (0.48) | KMT2AMEN1LMNANAMPTMMP13 | |
| SCHEMBL2931860 | 0.82 | KMT2A (0.53) | KMT2AMEN1PTGS2 | |
| SCHEMBL607096 | 0.81 | LMNA (0.46) | KMT2AMEN1LMNACYP2C19 | |
| SCHEMBL2926124 | 0.81 | PSMB5 (0.54) | KMT2AMEN1 | |
| SCHEMBL2934031 | 0.81 | CTSS (0.42) | RAB9APARP15 | |
| SCHEMBL2933903 | 0.81 | KDM4E (0.46) | RAB9A | |
| SCHEMBL2929285 | 0.80 | CNR2 (0.40) | LMNARAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KMT2A 2205/4885MEN1 2309/4885LMNA 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.